Ignite Creation Date:
2025-12-24 @ 7:12 PM
Ignite Modification Date:
2025-12-25 @ 4:47 PM
Study NCT ID:
NCT07218003
Status:
RECRUITING
Last Update Posted:
2025-10-24
First Post:
2025-10-14
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
A Phase 1/1b of RNDO-564 Single Agent or in Combination With Pembrolizumab in Bladder Cancer and Other Solid Tumors Associated With Nectin-4
Sponsor:
Rondo Therapeutics
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2025-10-30
Start Date Type:
ESTIMATED
Primary Completion Date:
2029-02-28
Primary Completion Date Type:
ESTIMATED
Completion Date:
2029-03-31
Completion Date Type:
ESTIMATED
First Submit Date:
2025-10-14
First Submit QC Date:
None
Study First Post Date:
2025-10-17
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-10-22
Last Update Post Date:
2025-10-24
Last Update Post Date Type:
ESTIMATED